Literature DB >> 21771899

Metabolism, LXR/LXR ligands, and tumor immune escape.

Vincenzo Russo1.   

Abstract

The mechanisms of tumor immune evasion have gained increasing interest among the tumor immunologists, because of their ability to suppress spontaneous and immunotherapy-elicited antitumor responses. Recent studies clearly show that the deletion of cells/molecules involved in tumor evasion is capable of restoring antitumor immune responses, ultimately leading to tumor rejection in mouse tumor models. These studies further support and strengthen the idea to target not only the cancer cell-intrinsic defects but also those affecting cells of the microenvironment, such as immune cells. The alterations of cancer cell metabolism are also emerging as important regulators of immune cell function, with particular emphasis on immune-escape mechanisms. Indeed, intermediate or final products of cancer cell metabolism may interfere with the function of immune cells infiltrating the tumor microenvironment. This review will focus on the role of cholesterol metabolism, with particular emphasis on the axis LXR/LXR ligands. This axis has been shown to affect DC migration to lymphoid organs, thus dampening the induction of successful antitumor responses. Finally, we will discuss whether this pathway may interfere with other immune cells infiltrating tumors and how to improve spontaneous and immunotherapy-based antitumor responses by counteracting this immune-escape mechanism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771899     DOI: 10.1189/jlb.0411198

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

1.  Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.

Authors:  Colin A Flaveny; Kristine Griffett; Bahaa El-Dien M El-Gendy; Melissa Kazantzis; Monideepa Sengupta; Antonio L Amelio; Arindam Chatterjee; John Walker; Laura A Solt; Theodore M Kamenecka; Thomas P Burris
Journal:  Cancer Cell       Date:  2015-06-25       Impact factor: 31.743

2.  Tumor LXR Expression is a Prognostic Marker for Patients with Hepatocellular Carcinoma.

Authors:  Houyong Long; Xingjun Guo; Shen Qiao; Qingxing Huang
Journal:  Pathol Oncol Res       Date:  2017-05-16       Impact factor: 3.201

3.  On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment.

Authors:  Gerald Eibinger; Günter Fauler; Eva Bernhart; Sasa Frank; Astrid Hammer; Andrea Wintersperger; Hans Eder; Akos Heinemann; Paul S Mischel; Ernst Malle; Wolfgang Sattler
Journal:  Exp Cell Res       Date:  2013-03-26       Impact factor: 3.905

4.  Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis.

Authors:  Peng Huang; Benson Kaluba; Xiao-Lin Jiang; Shi Chang; Xiao-Feng Tang; Lin-Feng Mao; Zhi-Peng Zhang; Fei-Zhou Huang
Journal:  Biomed Res Int       Date:  2018-02-18       Impact factor: 3.411

5.  Expression of NR1H3 in endometrial carcinoma and its effect on the proliferation of Ishikawa cells in vitro.

Authors:  Fang Fang; Dawei Li; Lu Zhao; Yue Li; Teng Zhang; Baoxia Cui
Journal:  Onco Targets Ther       Date:  2019-01-18       Impact factor: 4.147

6.  LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer.

Authors:  Katherine J Carpenter; Aurore-Cecile Valfort; Nick Steinauer; Arindam Chatterjee; Suomia Abuirqeba; Shabnam Majidi; Monideepa Sengupta; Richard J Di Paolo; Laurie P Shornick; Jinsong Zhang; Colin A Flaveny
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.